Form 4: Phathom Pharmaceuticals CEO Terrie Curran Sells Shares
SEC Form 4 Filing
Phathom Pharmaceuticals' CEO, Terrie Curran, sold 16,851 shares of common stock at an average price of $9.11 on March 22, 2024.
Summary
- Terrie Curran, the President and CEO of Phathom Pharmaceuticals, sold 16,851 shares of common stock on March 22, 2024.
- The shares were sold at a weighted average price of $9.11, with individual transactions ranging from $9.11 to $9.28.
- Following the transaction, Curran directly owns 410,784 shares of Phathom Pharmaceuticals, Inc.
- This includes 1,604 shares acquired under the employee stock purchase plan in January 2024.
- Curran also indirectly owns 3,840.16 shares through a 401(k).
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock sales by an executive. It doesn't inherently indicate positive or negative performance of the company.
Industry Context
This is a routine disclosure of an insider stock transaction. It's common for executives to periodically sell shares for personal financial management.
Stakeholder Impact
- The stock sale could have a minor impact on shareholder sentiment, depending on how the market interprets the transaction.
Key Dates
| Date | Description |
|---|---|
| January 2024 | 1,604 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan |
| 03/22/2024 | Date of stock sale transaction |
| 03/26/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.